Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 162
- Registration Number
- NCT06689241
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Efficacy of Aspirin in Preventing Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Target Recruit Count
- 60
- Registration Number
- NCT06635317
- Locations
- 🇲🇽
ISSSTEP, Puebla, Mexico
Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06531525
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing/Beijing, China
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- VarmX B.V.
- Target Recruit Count
- 16
- Registration Number
- NCT06517563
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 179
- Registration Number
- NCT06454630
- Locations
- 🇧🇬
Multi-profile Hospital for Active Treatment Hearth and Brain EAD, Pleven, Bulgaria
🇧🇬Multiprofile Hospital For Active Treatment Park Hospital Ltd., Plovdiv, Bulgaria
🇭🇺Budai Irgalmasrendi Korhaz, Budapest, Hungary
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06180889
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
Lovenox With Aspirin in Thawed Blastocyst Transfer
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Fertility Center of Las Vegas
- Target Recruit Count
- 130
- Registration Number
- NCT06133803
- Locations
- 🇺🇸
Fertility center of Las Vegas, Las Vegas, Nevada, United States
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 60
- Registration Number
- NCT06118957
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma
- Conditions
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Methodist Health System
- Target Recruit Count
- 100
- Registration Number
- NCT06025162
- Locations
- 🇺🇸
Methodist Dallas Medical Center Pharmacy, Dallas, Texas, United States
A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 90
- Registration Number
- NCT05895136
- Locations
- 🇫🇷
Hôpital Beaujon, Clichy, France
🇪🇸Hospital Universitari Vall d'Hebron-VHIR, Barcelona, Spain
🇮🇹IRCSS Azienda Ospedaliero Universitaria di Bologna Policlinico di Sant'Orsola, Bologna, Emilia Romagna, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.